Supporting adjuvanted vaccine development up to industrial scale

VFI engages in both scientific research collaborations and product development partnerships with industrial partners.

A prime example of such a partnership is our recent technology transfer to Seppic for the product development of VFI’s novel adjuvant SWE, where VFI has been supporting all scale-up and quality control processes.

VFI has experience in collaborating with industry partners, pharmaceutical and biotech companies, for over a decade. VFI considers collaborations with industry partners as long as such collaborations are in line with VFI’s global access policy and freedom-to-operate clauses.

Current projects

ISIDORe

“Integrated Services for Infectious Disease Outbreak Research” is an EU-funded large-scale project which assembles an unprecedented One Health-driven, integrated portfolio of cutting-edge research services and resources, dedicated to the study of epidemic-prone diseases including SARS-CoV-2 variants.

ISIDORe

VFI provides support on adjuvant development, non-GLP in vivo studies, technology transfer of adjuvants and provision of GMP adjuvant for use in clinical studies.
Visit website

Reference:
Marcandalli, J. et al. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. Cell 176, 1420-1431.e17 (2019).

Past

TRANSVAC

TRANSVAC is an EU-funded project aiming at developing a sustainable vaccine infrastructure for Europe.

TRANSVAC

VFI coordinates TRANSVAC activities and provides training as well as adjuvant and formulation services.
Visit website

Reference:
Geels, M. J. et al. TRANSVAC research infrastructure – Results and lessons learned from the European network of vaccine research and development. Vaccine 33, 5481–5487 (2015)

Activities

Contact us to discuss your project